Xia Bing, Guo Qing, Zhao Dan-Dan, Zhao Hai-Feng, Han Xiao-Ping, Wang Hui, Wu Xiao-Xiong, Zhang Yi-Zhuo
Department of Hematology, Cancer Hospital of Tianjin Medical University, Tianjin Key Laboratory of Tumor Prevention and Therapy, Tianjin 300060, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Dec;20(6):1392-7.
Alteration in the balance between cell apoptosis and proliferation is one of the pathophysiological mechanisms of the myelodysplastic syndromes (MDS). The question of whether the excessive apoptosis and/or proliferation predominantly involve the subset of progenitor cells (CD34(+) cells) or mature cells (CD34(-) cells) remains a controversial issue. This study was purpose to analyze the apoptosis and proliferation status of CD34(+) and CD34(-) cells in bone marrow (BM) of patients with MDS, to investigate the pathogenesis of MDS and to determine the relation of apoptosis and proliferation status of CD34(+) and CD34(-) cells with prognosis of MDS. The proportion of CD34(+) cells, the apoptosis and proliferation ratio (A/P) of CD34(+) and CD34(-) cells in BM of 40 patients with MDS, including 20 cases of high-risk MDS and 20 cases of low-risk MDS, and 10 normal persons as control were detected by flow cytometry; the influence of CD34(+) and CD34(-) cell apoptosis and proliferation levels on prognosis of MDS was evaluated by univariate and multivariate analysis of survival. The results showed that the proportion of CD34(+) cells in BM of high-risk MDS patients was significantly higher than that in BM of low-risk MDS patients and in normal BM [(1.92 ± 0.10)%, (1.09 ± 0.04)%, (1.03 ± 0.05)% respectively]. The apoptotic rates (AR) of both CD34(+) and CD34(-) cells were significantly higher in low-risk MDS [(54.75 ± 2.18)%, (80.36 ± 1.68)%] than in high-risk MDS [(24.87 ± 2.69)%, (23.12 ± 1.23)%] and in normal BM [(18.51 ± 2.74)%, (20.98 ± 2.21)%]. When compared between CD34(+) cells and CD34(-) cells in low-risk MDS, a greater AR of CD34(-) cells was found. However, the higher proliferative rate of CD34(+) cells was observed in high-risk MDS. In low-risk MDS, a higher A/P ratio was found in CD34(-) cells than in CD34(+) cells; whereas this ratio was equalized or inverted in high-risk MDS. In addition, the survival and prognosis correlated significantly with AR of CD34(+) cells. It is concluded that the early MDS is predominantly associated with excessive apoptosis of the mature CD34(-) cells. The proliferation rate of cells increases with the disease progression in MDS subsets, especially, in the subset of CD34(+) cells. Surprisingly, the apoptosis of CD34(+) cells may be a useful prognostic factor, and the inhibition of apoptotic mechanisms may induce the transformation of MDS to leukemia.
细胞凋亡与增殖之间平衡的改变是骨髓增生异常综合征(MDS)的病理生理机制之一。过度凋亡和/或增殖主要涉及祖细胞亚群(CD34(+)细胞)还是成熟细胞亚群(CD34(-)细胞)的问题仍然存在争议。本研究旨在分析MDS患者骨髓中CD34(+)和CD34(-)细胞的凋亡与增殖状态,探讨MDS的发病机制,并确定CD34(+)和CD34(-)细胞的凋亡与增殖状态与MDS预后的关系。采用流式细胞术检测40例MDS患者(包括20例高危MDS和20例低危MDS)及10例正常对照者骨髓中CD34(+)细胞比例、CD34(+)和CD34(-)细胞的凋亡与增殖比率(A/P);通过生存单因素和多因素分析评估CD34(+)和CD34(-)细胞凋亡与增殖水平对MDS预后的影响。结果显示,高危MDS患者骨髓中CD34(+)细胞比例显著高于低危MDS患者骨髓及正常骨髓[分别为(1.92±0.10)%、(1.09±0.04)%、(1.03±0.05)%]。低危MDS中CD34(+)和CD34(-)细胞的凋亡率(AR)均显著高于高危MDS[分别为(54.75±2.18)%、(80.36±1.68)%]及正常骨髓[分别为(18.51±2.74)%、(20.98±2.21)%]。低危MDS中,CD34(-)细胞的AR更高。然而,高危MDS中观察到CD34(+)细胞的增殖率更高。在低危MDS中,CD34(-)细胞的A/P比值高于CD34(+)细胞;而在高危MDS中该比值趋于平衡或倒置。此外,生存及预后与CD34(+)细胞的AR显著相关。结论是早期MDS主要与成熟CD34(-)细胞的过度凋亡有关。在MDS亚组中,细胞增殖率随疾病进展而增加,尤其是在CD34(+)细胞亚组中。令人惊讶的是,CD34(+)细胞的凋亡可能是一个有用的预后因素,抑制凋亡机制可能诱导MDS向白血病转化。